Narcolepsy
A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)
Subtype terms (1)
More specific conditions that are subtypes of Narcolepsy in the MeSH hierarchy.
- Cataplexy
4 drugs (3 approved, 1 experimental)
Drugs by status
Approved for this indication (11)
Phase 3 trials (4)
Phase 2 trials (12)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (17)
- Pfizer
- Alza
- Axsome Therapeutics, Inc.
- GlaxoSmithKline
- Suven Life Sciences Limited
- Theranexus
- Balance Therapeutics
- Taisho Pharmaceutical
- National Institute of Neurological Disorders and Stroke (NINDS)
- Maastricht University
- Emory University
- King Saud University
- King Saud Medical City
- University of Montpellier
- Aerial BioPharma, LLC
- Georgia Research Alliance
- American Academy of Sleep Medicine
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (6)